Skip to main content
PLOS One logoLink to PLOS One
. 2023 Apr 19;18(4):e0283549. doi: 10.1371/journal.pone.0283549

Opioid-related deaths during hospital admissions or shortly after discharge in the United Kingdom: A thematic framework analysis of coroner reports

Dan Lewer 1,2,*, Thomas D Brothers 1,3, Magdalena Harris 4, Kirsten L Rock 5, Caroline S Copeland 5
Editor: Charlotte Lennox6
PMCID: PMC10115296  PMID: 37075021

Abstract

Background

People who use heroin and other illicit opioids are at high risk of fatal overdose in the days after hospital discharge, but the reasons for this risk have not been studied.

Methods

We used the National Programme on Substance Abuse Deaths, a database of coroner reports for deaths following psychoactive drug use in England, Wales, and Northern Ireland. We selected reports where the death occurred between 2010 and 2021, an opioid was detected in toxicology testing, the death was related to nonmedical opioid use, and death was either during an acute medical or psychiatric hospital admission or within 14 days after discharge. We used thematic framework analysis of factors that may contribute to the risk of death during hospital admission or after discharge.

Results

We identified 121 coroners’ reports; 42 where a patient died after using drugs during hospital admission, and 79 where death occurred shortly after discharge. The median age at death was 40 (IQR 34–46); 88 (73%) were male; and sedatives additional to opioids were detected at postmortem in 88 cases (73%), most commonly benzodiazepines. In thematic framework analysis, we categorised potential causes of fatal opioid overdose into three areas: (a) hospital policies and actions. Zero-tolerance policies mean that patients conceal drug use and use drugs in unsafe places such as locked bathrooms. Patients may be discharged to locations such as temporary hostels or the street while recovering. Some patients bring their own medicines or illicit opioids due to expectations of low-quality care, including undertreated withdrawal or pain; (b) high-risk use of sedatives. People may increase sedative use to manage symptoms of acute illness or a mental health crisis, and some may lose tolerance to opioids during a hospital admission; (c) declining health. Physical health and mobility problems posed barriers to post-discharge treatment for substance use, and some patients had sudden deteriorations in health that may have contributed to respiratory depression.

Conclusion

Hospital admissions are associated with acute health crises that increase the risk of fatal overdose for patients who use illicit opioids. Hospitals need guidance to help them care for this patient group, particularly in relation to withdrawal management, harm reduction interventions such as take-home naloxone, discharge planning including continuation of opioid agonist therapy during recovery, management of poly-sedative use, and access to palliative care.

Background

There are well-established time periods of heightened risk for fatal opioid overdose, including release from prison [1,2], discharge from community or inpatient drug treatment [35], and the weeks after a non-fatal drug overdose [6]. Recent research has also found an elevated risk after a hospital stay for medical treatment [710]. For example, a study in England found that the risk of fatal overdose was increased four-fold in the two days after hospital discharge; and 1 in 14 opioid-related deaths happen in the two weeks after discharge from an acute medical or psychiatric ward [7]. This study also found that people who use illicit opioids who are admitted to hospital for reasons other than a drug overdose appeared to have a similar likelihood of dying from an opioid overdose while admitted to hospital as when they are in the community, despite the immediate availability of emergency care.

The mechanisms behind these risks have not been studied. However, aspects of hospital policy and practice that may harm patients who use illicit drugs have been studied. Together these issues have been called the ‘hospital risk environment’ [11], which may offer some possible explanations for risk associated with hospital admissions and discharges. Qualitative and quantitative research with people who use illicit opioids suggest that in-hospital drug use is common [1215], and ‘zero tolerance’ approaches may lead people to use drugs in riskier ways such as in locked toilet cubicles. Patients report delayed or low doses of opioid agonist therapy (OAT), in part due to conservative or unclear hospital policies in relation to OAT [16,17]. This may lead patients to secretly stockpile drugs including prescribed OAT because they anticipate inadequate pain or withdrawal management [18]. Patients who use illicit drugs also report stigmatising attitudes among staff [19]. Poor pain and withdrawal management and experiences of stigma can lead to patient-directed discharge [20], which is consistently associated with poor health outcomes and readmission [21,22]. Patients who abstain from drugs or do not receive OAT during a hospital stay may lose opioid tolerance [18], increasing the risk on resumption of opioid use.

Existing studies into overdose deaths around the time of a hospital admission [710] have used quantitative analyses of national hospital databases, which have limited contextual information about patients, health services, and social conditions. An understanding of these factors could guide preventative strategies. We therefore studied coroners’ reports, which include narrative reports about the circumstances of death. Since these reports vary in terms of format and length, they are sometimes analysed using qualitative methods such as thematic framework analysis [23,24]. Our research question was: what factors contribute to the risk of fatal overdose around the time of a hospital admission?

Methods

Dataset: The National Programme on Substance Abuse Deaths (NPSAD)

NPSAD was set up in 1997 to collate coroner reports on deaths that are related to psychoactive drugs. Coroners in England, Wales, and Northern Ireland voluntarily report a death to NPSAD if the death was considered drug-related, the decedent was known to use illicit drugs, or illicit drugs were detected in post-mortem toxicology testing. As an estimate of coverage, the Office for National Statistics reported 22,497 deaths between 2010 and 2021 where an opioid was mentioned on the death certificate [25], and NPSAD includes 11,831 deaths with an opioid identified in toxicology reports over the same period, suggesting approximately half of relevant deaths are included.

Coroners’ investigations use a variety of sources, including statements from witnesses, family, and friends; General Practitioner records; reports from first responders such as police and paramedics; hospital reports; substance abuse team reports; and post-mortem and toxicology reports. Coroners submit summary reports to NPSAD, which are transposed into a database with structured fields including age, sex, housing status, employment status, and drugs detected at post-mortem. We did not have access to hospital records beyond information in the coroners’ report.

The King’s College London Biomedical & Health Sciences, Dentistry, Medicine and Natural & Mathematical Sciences Research Ethics Sub-Committee re-confirmed (August 2022) that analyses of NPSAD do not require ethics review as all subjects are deceased.

Selection of reports

We included reports where: (a) the date of death was between 1 January 2010 and 1 November 2021 (few deaths were included after May 2021 due to the time taken by coroners to investigate and report deaths); (b) an opioid was identified in toxicology reports; (c) the death was related to nonmedical opioid use, ie. use of illicit or ‘diverted’ opioids, (d) the death was either during an acute medical or psychiatric hospital admission or within 14 days of discharge. We excluded deaths if: (a) the duration between discharge and death was not known; (b) death was on hospital premises but the person was not admitted, for example if they visited the hospital to use a public toilet; (c) the person was admitted to hospital for treatment after a drug overdose in the community, and died because of that overdose, rather than due to further illicit drug use while in hospital.

We identified relevant deaths following the process shown in Fig 1. We first extracted cases where an opioid was detected in toxicology reports, and either hospital was the place of death or the text strings ‘hosp’, ‘admission’, ‘discharge’, or ‘infirmary’ appeared in any field. We screened the structured fields to exclude cases unlikely to meet inclusion criteria. Two authors (DL and CC) double-screened a sample (365/2,443; 15%), with agreement of 98.4% and Cohen’s kappa of 0.88. We then retrieved the original reports and determined whether they met inclusion criteria.

Fig 1. Flow chart of the process of selecting coroner reports for analysis.

Fig 1

NPSAD = National Programme on Substance Abuse Deaths.

Analysis

We used thematic framework analysis [26,27] to identify and explore factors that may contribute to the risk of fatal overdose around the time of a hospital admission. Framework analysis involves organising codes into categories developed by the research team. The codes are revised and updated as analysis progresses [28]. We chose this method because we had a large number of reports with inconsistent detail; many with just a few words and some with several pages of narrative. The framework analysis meant that each report could contribute to the framework. We also chose to use framework analysis because wanted to explain a phenomenon (hospital-related overdose risk) rather than develop theory.

In developing the framework, we used an iterative deductive and inductive approach. This means a combination of building on a-priori theory (deductive) and identifying themes from the data (inductive). Our deductive work was informed by literature review, existing concepts relating to the ‘risk environment’ in hospitals [11,29], and discussions amongst the research team before analysis. We developed the framework in five stages: (a) we selected 25 random cases, which three authors (DL, CC, and TB) independently open-coded in triplicate. This involved adding tags and notes to the free-text coroner reports; (b) we reviewed the codes together and created an initial framework by identifying themes and grouping the themes into categories; (c) we applied the initial framework to all cases, with one author (DL, CC, TB, MH, or KR) coding each case; (d) we reviewed the results collaboratively and revised the framework in several iterative rounds.

We described the thematic framework, including representative quotes from coroners’ reports. Although reports are publicly available (for example via Freedom of Information requests), we edited quotes to minimise the chance that an individual might be identified in our report. These edits included assigning a male or female gender at random, using a different name, replacing dates with random dates, and replacing hospital names with fictitious names and locations.

Ethics and approvals

The King’s College London Biomedical & Health Sciences, Dentistry, Medicine and Natural & Mathematical Sciences Research Ethics Sub-Committee re-confirmed (August 2022) that analyses of NPSAD do not require ethics review as all subjects are deceased. In addition, this manuscript has been reviewed by the ethics committee and NPSAD executive committee to ensure that published data and quotes respect confidentiality of decedents.

Results

Characteristics of cases

We identified 121 cases that met our inclusion criteria. 42 people died while admitted to hospital and 79 died in the 14 days after discharge. The two groups had similar demographic characteristic: the median age was 40 (IQR 34–46) and 88/121 (73%) were male. The age and sex distributions reflect the characteristics of people who died after using opioids in England [7,25]. The largest proportions were in the North West and Yorkshire and the Humber. The geographical distribution may reflect differences in the prevalence of opioid use and differences in coroners’ participation in NPSAD.

70/121 (58%) were admitted to hospital for treatment of medical problems (rather than a drug overdose) and 32/121 (26%) were admitted due to a drug overdose. We could not determine the cause of hospital admission for the remaining cases. A large proportion had other sedatives in addition to opioids identified at post-mortem. Benzodiazepines were particularly common and were detected in over half of toxicology reports. Characteristics of study participants are summarised in Table 1.

Table 1. Characteristics of study participants; data from NPSAD 2010–2021.

Variable Level Died during hospital admission Died in the 14 days after hospital discharge Total
Total 42 (100.0) 79 (100.0) 121 (100.0)
Age 18–24 1 (2.4) 4 (5.1) 5 (4.1)
25–34 13 (31.0) 14 (17.7) 27 (22.3)
35–44 16 (38.1) 38 (48.1) 54 (44.6)
45–54 8 (19.0) 20 (25.3) 28 (23.1)
55–64 3 (7.1) 2 (2.5) 5 (4.1)
65+ 1 (2.4) 1 (1.3) 2 (1.7)
Median [IQR] 39 [33–46] 40 [36–46] 40 [34–46]
Sex Female 10 (23.8) 23 (29.1) 33 (27.3)
Male 32 (76.2) 56 (70.9) 88 (72.7)
Housing status Housed—alone 18 (42.9) 30 (38.0) 48 (39.7)
Housed—with family or friends 6 (14.3) 24 (30.4) 30 (24.8)
No fixed abode 1 (2.4) 8 (10.1) 9 (7.4)
Not known 17 (40.5) 17 (21.5) 34 (28.1)
Region East Midlands 1 (2.4) 1 (1.3) 2 (1.7)
East of England 6 (14.3) 4 (5.1) 10 (8.3)
London 1 (2.4) 2 (2.5) 3 (2.5)
North East 2 (4.8) 1 (1.3) 3 (2.5)
North West 7 (16.7) 30 (38.0) 37 (30.6)
Northern Ireland 1 (2.4) 4 (5.1) 5 (4.1)
South East 5 (11.9) 8 (10.1) 13 (10.7)
South West 2 (4.8) 1 (1.3) 3 (2.5)
West Midlands 3 (7.1) 12 (15.2) 15 (12.4)
Yorkshire and the Humber 13 (31.0) 13 (16.5) 26 (21.5)
Other 1 (2.4) 3 (3.8) 4 (3.3)
Discharge against medical advice Yes NA 28 (35.4) NA
No NA 33 (41.8) NA
Unknown NA 18 (22.8) NA
Admitted due to drug overdose Yes 6 (14.3) 26 (32.9) 32 (26.4)
No 27 (64.3) 43 (54.4) 70 (57.9)
Unknown 9 (21.4) 10 (12.7) 19 (15.7)
Type of hospital Acute medical 29 (69.0) 66 (83.5) 95 (78.5)
Psychiatric 13 (31.0) 9 (11.4) 22 (18.2)
Unknown 0 (0.0) 4 (5.1) 4 (3.3)
Classes of sedatives found at post-mortem (in addition to opioids) Antidepressants 11 (26.2) 29 (36.7) 40 (33.1)
Antipsychotics 7 (16.7) 13 (16.5) 20 (16.5)
Benzodiazepines 22 (52.4) 48 (60.8) 70 (57.9)
Gabapentinoids 6 (14.3) 25 (31.6) 31 (25.6)
Z-drugs 5 (11.9) 12 (15.2) 17 (14.0)
At least one 27 (64.3) 61 (77.2) 88 (72.7)
Classes of sedatives prescribed (other than opioids) Antidepressants 11 (26.2) 29 (36.7) 40 (33.1)
Antipsychotics 8 (19.0) 12 (15.2) 20 (16.5)
Benzodiazepines 8 (19.0) 17 (21.5) 25 (20.7)
Gabapentinoids 6 (14.3) 15 (19.0) 21 (17.4)
Z-drugs 3 (7.1) 12 (15.2) 15 (12.4)
At least one 16 (38.1) 43 (54.4) 59 (48.8)

Thematic framework analysis of factors that may contribute to the risk of opioid overdose during or shortly after hospital admissions

We developed a framework consisting of eight themes organised into three categories: (a) hospital actions and policies; (b) high risk use of sedatives; and (c) declining health. Themes and categories are summarised in Table 2.

Table 2. Themes relating to the risk of opioid-related deaths during hospital admissions or shortly after hospital discharge.

Category Themes Number of cases
(n = 121)
Example case
(a) Hospital actions and policies (1) Concealing drug use, or using drugs in unsafe places 23 Admitted to hospital due to stomach pain. Medical staff were aware of drug and alcohol use. Five days after admission the patient was discovered in a hospital bathroom with drug paraphernalia [ID111].
(2) Discharge against medical advice leading to missed opportunities for care 30* Admitted to hospital after a heroin overdose and naloxone was administered. Left hospital against medical advice later that evening, and was found dead at a relative’s house after using heroin and benzodiazepines [ID17].
(3) Poor discharge location, such as the street or a temporary hostel 16 Admitted to hospital after a suspected overdose and being found unconscious in a public place. Admitted to hospital for three weeks, and then discharged to a hotel. Did not respond to knocking on the day of check-out from the hotel [ID60].
(4) Expecting low quality care or bringing own treatment 11 Admitted for treatment of pneumonia. Brought additional, non-prescribed methadone into hospital and died after using this methadone [ID51].
(b) High risk use of sedatives (5) Increased use of sedatives due to acute illness 28 Had a fall and was admitted to hospital with a fractured wrist and dislocated shoulder. Was discharged, and then died after taking additional opiates and antidepressants to manage pain [ID45].
(6) Loss of tolerance to opioids 35 Medical records of using heroin, crack cocaine, alcohol, and had a methadone prescription. Admitted to hospital due to pneumonia and detoxed during the admission. Died the day after discharge [ID46].
(c) Declining health (7) Poor health or mobility reducing access to treatment for substance use 9 History of heroin use. Had COPD and cellulitis on legs and feet, which severely affected mobility and may have prevented access to community drug treatment services. Admitted to hospital with shortness of breath, but self-discharged. Later died at home after using heroin. Post-mortem toxicology suggested methadone was not recently used, despite having a methadone prescription [ID6].
(8) Acute exacerbations of long-term conditions or sudden deteriorations in health, increasing vulnerability to fatal overdose 51 Medical history of asthma and heroin use. Admitted to hospital with respiratory failure and treated for asthma exacerbation. Self-discharged the day after admission. Went to bed that evening with shortness of breath and died after using heroin [ID90].

* In two reports where the death occurred during a hospital admission, discharge against medical advice was noted for a previous admission, hence 30 reports have discharge against medical advice in this table, compared to 28 in Table 1.

(a) Hospital actions and policies

Four themes related to hospital actions and policies: concealing drug use or using drugs in unsafe places; self-discharge leading to missed opportunities for care; poor discharge location such as the street or a temporary hostel; and expecting low quality care or the patient bringing their own treatment.

Many reports indicated covert drug use during a hospital admission. These included hospital staff reporting that they had seen patients trying to hide drug use, temporarily leaving a ward and returning intoxicated, and patients found unconscious or dead with evidence of drug use, such as a syringe or “heroin powder found at the scene in clothes pocket” [ID82]. One patient was admitted due to an infected injecting wound in the groin, and had recently returned to the ward after a scan:

“At approximately 0417hrs a nurse witnessed Paul to be fumbling around with something in a pouch and doing something around his groin area. A short while later, a healthcare assistant noticed he looked a lot more unwell, also noticed Paul was bleeding from the right of his groin again. Paul was losing a lot of blood” [ID10].

Some reports stated that patients had community-based prescriptions of OAT, but it was unclear if OAT was continued in hospital. In one report, a person who used heroin and had a methadone prescription was admitted to hospital due to a pulmonary embolism and was “believed to have been using heroin (by injection) whilst being treated” [ID117]. The report did not mention a methadone prescription in hospital. Similarly, another patient had an infection and was admitted to hospital for intravenous antibiotics. The coroner’s report stated that they used heroin while in hospital. Although they had a long history of drug and alcohol problems and a prescription of methadone prior to admission, methadone was not identified in post-mortem toxicology testing which may suggest it was not provided in hospital [ID83]. Insufficient OAT or opioid withdrawal management may have led to illicit drug use, and some patients underwent opioid ‘detox’ (withdrawal management) in hospital without initiation of OAT, which is known to increase risks of fatal overdose.

Many reports included accounts of discharge against medical advice. These accounts typically use language such as “absconded” or “failure to comply”. One patient who had endocarditis (a serious infection of the heart) was described as “constantly disappearing off the ward for cigarettes” and that they “failed to comply with [the] hospital”. Two days after admission, this patient left hospital, and was later found unresponsive at a relative’s house [ID52]. Many accounts of discharge against medical advice suggested drug use very shortly after leaving hospital, and often in risky places. For example, one patient left hospital after being admitted due to self-harm, and immediately took a fatal overdose:

“The deceased had a past medical history of alcohol and substance misuse and deliberate self-harm. He was admitted to King George V Hospital on 7th February 2013 with self-inflicted wounds to the wrist. He also requested assistance with detoxing and he showed signs of withdrawal. A detox regime was commenced. On 12th February 2013, he absconded from the ward and was readmitted following a cardiac arrest. He was said to have taken cocaine, heroin, and alcohol, and collapsed outside a friend’s room” [ID9].

Both for patients who left hospital against medical advice, and for those who completed treatment, the location of discharge was often poor. After leaving hospital, patients in our sample were recorded as sleeping in locations such as temporary hostels, hotels, private vehicles, tents, or on the street. Many used drugs in an unsafe or unfamiliar place while unwell, and reports included accounts of patients found dead in these locations. One patient was discharged from hospital after an overdose of benzodiazepines and antidepressants. This patient was discharged to supported accommodation, but the coroner’s report suggests that staff were not present that night and were unaware of this recent overdose. The patient later died from an overdose of heroin and other sedatives [ID1].

In some reports, patients brought their own drugs into hospital, which may reflect expectations that opioid withdrawal or pain would not be managed. One patient was admitted with gastrointestinal issues and liver cirrhosis. After they were found unconscious, “staff found an empty methadone bottle in her name and some brown and white tablets not prescribed by the hospital” [ID49]. In another case, a patient was admitted to hospital for a respiratory infection and had a medical history including obstructive hiatus hernia, sleep apnoea, obesity, and alcohol and cocaine use. During the hospital admission this patient told hospital staff that they used morphine prescribed to a family member. This patient was discharged after one day in hospital and found dead three days later with morphine contributing to death [ID13].

(b) High risk use of sedatives

Many of the coroner reports included evidence that people who died took multiple sedatives or drank alcohol in addition to using opioids. Out of the cases included in our sample, 59/121 (49%) had prescriptions of multiple sedatives and 88/121 (73%) had another sedative in addition to opioids detected at post-mortem, most commonly benzodiazepines (Table 1). While use of sedatives may not be unusual among people who use illicit drugs, some reports suggested increased use of sedatives to manage symptoms of acute illness, pain, mental health crises, or alcohol withdrawal. For example, a patient was admitted to hospital for 13 days due to severe back pain. The patient’s medical notes included use of heroin, crack cocaine, and dependence on unspecified prescription drugs. On discharge, the patient was given a “large amount” of take-home morphine, diazepam, and pregabalin. They were discharged to temporary accommodation and died three days later due to a drug overdose [ID99]. In several cases, a mental health crisis appears to have caused hospital admission and risky sedative use. For example, one individual attended hospital after taking several sedatives. They left hospital before being assessed, and later died from an overdose attributed to opioids, pregabalin, and benzodiazepines:

“The deceased had a history of alcoholism, polysubstance abuse, dissocial personality traits, depression and schizophrenia. She was taken from Queen Mary Street to the Accident and Emergency Department of the University Hospital Manchester, by ambulance at around 10.15am on the 4th July 2012. When triaged, she complained of low mood thoughts of self-harm, visual and auditory hallucinations. She stated that she had taken Lyrica tablets, Diazepam and Xanax tablets the previous day … A preliminary mental health assessment was started but a full assessment could not be completed as the deceased was under the influence of drugs. As a result she was admitted in order to allow her time to become medically fit for the assessment to take place but the deceased left the hospital” [ID108].

In many cases multiple sedatives were present in toxicology reports, but we could not determine whether using sedatives in that way was unusual for a given individual. For example, one individual had a history of heroin use and prescriptions including methadone, morphine, pregabalin, mirtazapine, and quetiapine. They were admitted to hospital for treatment of pneumonia. This patient died on the day after discharge after using heroin, diazepam, and drugs prescribed during the hospital admission [ID3]. In cases such as this, symptoms of an acute illness may have led individuals to use higher doses of prescribed or illicit drugs for symptom management. Toxicology reports also commonly identified unregulated and non-medical ‘street’ benzodiazepines such as etizolam and flualprazolam. We were unable to determine if use of these ‘street’ benzodiazepines was established before the time hospital admission or was initiated following discharge.

Hospital admissions may also be associated with loss of tolerance to opioids and other sedatives. This may be due to periods of abstention while in hospital because drugs are unavailable, intentional ‘detox’ in hospital, or insufficient opioid withdrawal management or OAT. Some of these issues are explored in the themes under ‘hospital actions and policies’, above. This appears particularly important for patients in psychiatric hospitals who may have long stays or more limited access to illicit drugs. One patient was an involuntary inpatient being treated for psychosis for eight weeks. They left the hospital and died the next day after using heroin [ID22]. Another patient was detained for ten days in a psychiatric hospital died shortly after release:

“The deceased was a long-standing known drug user and alcoholic … He had recently been detained between the 8th to the 18th November 2021 at the Ivy Ward and it is possible he had lost a level of tolerance to the drugs he had been injecting or consuming. Postmortem samples demonstrated the deceased had recently used heroin, methadone, pregabalin, cocaine, paracetamol, mirtazapine, amitriptyline, quetiapine, diazepam, and omeprazole” [ID78].

The coroners’ reports often showed that hospital staff were aware of patients’ high risk sedative use, which may suggest there were opportunities to mitigate this risk, for example through initiation or continuation of OAT or provision of take-home naloxone. From individual reports, we were usually not able to determine whether hospitals attempted to mitigate the risk of overdose.

(c) Declining health

Most hospital admissions were for treatment of physical health problems and exacerbations of long-term conditions, rather than drug-related problems such as overdoses and intoxication. Many patients had poor respiratory health or bacterial infections. In some reports these physical health problems meant that patients were unable to access community support after discharge. In one case, hospital staff identified poor conditions in a patient’s home and the patient’s difficulty in attending a community drug treatment service due to mobility problems:

“James was an intravenous drug user who used to inject in his groin. On 17th November 2017, he was admitted to hospital with a two-day history of sudden-onset pain in his left groin … accompanied by feeling weak and feverish … He had stopped methadone treatment a month before. On 19th November, he underwent surgical exploration of the groin, at which a large pseudoaneurysm was revealed … By 5th December 2017, James was deemed fit to be discharged with a dressing. On 9th December, he was reviewed in hospital to assess his current health and social issues: several problems were identified. These included the insanitary condition of James’s flat, his difficulties accessing methadone maintenance services owing to limitation by pain of his ability to walk to the clinic” [ID110].

Health-related barriers to healthcare were evident in many reports. Another patient had long-term problems with drugs and respiratory health, but limited support for these problems. This patient was admitted to hospital for treatment of an acute exacerbation of chronic obstructive pulmonary disease (COPD), was discharged home, and died six days later after using heroin. A General Practitioner report stated that:

“Andrew had a longstanding alcohol problem and heroin addiction, dating back at least 20 years and diagnosed with COPD 11 years ago… Andrew was admitted to Hastings Hospital six times in the year prior to his death, with chest infection and respiratory failure … On 2 May 2018 I had a telephone consultation with Community Matron regarding low oxygen saturations … Andrew was advised to have admission to hospital immediately, but the patient refused … He felt lonely and helpless but declined hospitalisation … we agreed that Andrew was a Palliative Care case now. The patient was admitted to hospital on 4 May 2018 by 999 ambulance after self-referral and discharged on 9 May 2018 [with a diagnosis of infective exacerbation of COPD]. The patient then attended by ambulance on 15 May 2018 having been found by his mother … Unfortunately, the patient had poor history of attending outpatient appointments, which were arranged for him–both endocrinology team and respiratory medicine … I am not aware of a Drug and Alcohol Team being involved with this patient’s care for some years [ID105].

Some coroner reports similarly suggested that patients might have reduced mobility, for example due to severe COPD or a long hospital admission, and documented a lack of opioid agonist therapy, though the link between mobility and drug treatment was not explicit. One patient with COPD and mobility problems due to soft tissue infections made multiple unsuccessful attempts to be assessed for shortness of breath. Although this patient had a methadone prescription, methadone was not identified in post-mortem toxicology testing:

“Michelle had a previous medical history of cellulitis of the foot, drug addiction therapy (methadone), and COPD. Michelle had a makeshift bed in the kitchen due to her poor mobility as she had abscesses on both of her feet and legs, she was in ill health and had been admitted to hospital recently (twice in one week). On 12th January Michelle’s partner had called an ambulance due to her being short of breath. Paramedics attended and conducted basic health checks but Michelle refused to go with them. Michelle was later taken to hospital with a friend but as she was left for approximately 12 hours without being seen, she got fed up and left. The following day Michelle’s partner called emergency services again as her breathing was getting worse. Michelle went with the ambulance to hospital where she only stayed for a few hours as she stated that she was left again” [ID6].

Many coroner reports described acute exacerbations of long-term conditions or other sudden deteriorations of health, which may have led to increased vulnerability to fatal overdose. These reports most frequently described acute respiratory health problems such as pneumonias and other acute exacerbations of COPD. For example, one report described a patient who died six days after being discharged for treatment of pneumonia:

“Discharged from hospital 9 August 2014 having suffered pneumonia and sepsis. On 15 August 2014 he was struggling to breathe. Ambulance called, there was a [do not attempt cardiopulmonary resuscitation] order in place, and he was declared deceased by paramedics. History of heroin, crack, and cannabis use, HIV, COPD with infective exacerbations” [ID113].

In several cases including the one above, the cause of death was listed as a combination of opiates or other sedatives and COPD. Several coroners’ reports described decompensations of liver disease, often with comorbidities, which may have contributed to the risk of opioid overdose through impaired metabolism, encephalopathy, or frailty. One patient had a history of alcohol-related liver cirrhosis, chronic pancreatitis, and secondary diabetes. They were admitted to hospital due to “severe pancreatitis” and died after taking methadone in hospital [ID89]. In this case, it was unclear whether methadone was prescribed.

Some reports described multiple health problems, very severe health problems, or patients who were near the end of life. In these cases, the use of palliative care pathways or the availability of specialist palliative care services was unclear from the coroners’ reports.

Discussion

Key findings

In this qualitative analysis of coroner’s reports, we identified several factors potentially contributing to excess risk of opioid-related deaths soon after hospital discharge. These include the risk of using drugs in a hospital setting, such as using drugs in locked bathrooms; high-risk use of sedatives due to acute illnesses and loss of opioid tolerance; and the effect of poor health on respiratory depression and access to community drug treatment services. The coroners’ reports show that patients’ use of drugs was often known to hospital staff. Deaths may be prevented by clearer policies to help these patients remain in hospital, complete treatment, and discharge with a plan to access stable housing and services such as OAT while recovering.

Comparisons with previous studies

We are not aware of previous research that attempts to explain the excess risk of fatal overdose after hospital discharge. However, other research has sought to explain why risk increases at other critical moments. One such critical moment is release from prison, which has a well-known association with fatal drug poisoning [1,2]. One explanatory model [30] includes four pathways: (a) ‘underlying factors’ including opioid use among people in prison, limited access to OAT, health states including pain and mental health problems, and trauma; (b) ‘intermediate factors’ including disrupted social networks, interruptions in care, and stigma; (c) ‘proximate factors’ including solitary use, insufficient naloxone access, and poly-drug use; and (4) ‘biological factors’ including reduced opioid tolerance. Hospital admissions have many differences to prison stays, including the typically shorter duration (the mean custodial sentence for drug offenses in England and Wales was 40 months in 2020 [31]; compared to 9 days for hospital admissions prior to drug-related deaths [7]), that all hospital patients are unwell, and most hospital admissions are voluntary. However, the factors that may explain the large number of deaths after prison release also plausibly explain deaths after hospital discharge; though some factors are likely to be more important, such as health states.

Another critical moment is cessation of OAT, which may confer risk through loss of tolerance to opioids [3]. For example, a study in England showed that mortality rates during the first two weeks after discharge from methadone or buprenorphine treatment was nine times that of patients on treatment [32].

There may be common processes that increase risk across these critical moments. A study of non-fatal overdoses in Canada found several such critical moments, including hospital discharge, entry to prison, release from prison, new prescriptions of sedatives, discontinuing antipsychotics, and exiting methadone treatment [10]. These events are associated with unusual drug use, changing tolerance, stressful life events, and disruptions to treatment and support services. The authors of this study concluded that better continuity of care, particularly OAT, during periods of transition could prevent overdoses.

Relevance for policy and practice

The practical implications of this study relate to acute hospitals and how they support patients who use illicit opioids. Recent reviews of hospital policies in England [16] and the United States [17] showed that many require disproportionate caution in prescribing OAT, such as requiring urine screens or slow titration. In addition, qualitative research has shown that many hospital staff do not feel they have sufficient knowledge to treat patients who are dependent on opioids [19,33]. As a result, patients who use opioids may delay or interrupt hospital care [18]. Our results suggest that hospitals may be able to provide better support in five areas.

First, providing sufficient OAT during periods of acute illness. The accounts we reviewed show that hospital patients may use drugs covertly, and OAT may help prevent this. Basic training on substance use and OAT could help medical staff initiate and continue OAT for patients during hospital treatment. After discharge, patients may have reduced mobility and be unable to attend community pharmacies or OAT clinics, and therefore use illicit drug dealers who are willing to visit clients’ homes. Some cases in our study were unable to access OAT due to illness and died after using illicit drugs. In these cases, hospital staff may need to work with community drug services to arrange home visits and delivery of medication.

Second, providing harm reduction interventions that recognise illicit drug use is likely to happen. Naloxone may be particularly beneficial when a patient comes to hospital with a friend or family member. Hospitals have piloted take-home naloxone, particularly in emergency departments [34,35], though this is uncommon in part due to lack of understanding of naloxone [34]. Tolerated and managed use of illicit drugs may prevent the riskiest situations such as patients using drugs alone in locked bathrooms and toilet cubicles, which was common in our study. Supervised consumption rooms have been set up in some hospitals in Canada [36,37] and evaluations suggest they are safe and improve medical care, including by prevention of early discharge due to opioid withdrawal [38].

Third, improving discharge planning for patients who use drugs. In the coroners’ reports in our study, many discharges appeared sudden and unsupported, with patients leaving unilaterally or going to an unsafe location. Further research into the clinical circumstances of ‘discharge against medical advice’ may inform potential interventions. For example, staff may have opportunities to discuss patients’ needs or provide pre-prepared packs including naloxone and emergency contacts. Even when patients are considered ready for discharge, some do not have a suitable discharge location. Our study included accounts of patients using drugs in cars, public toilets, and on the street after hospital discharge. There is substantial pressure on acute hospitals to discharge patients and free up beds [39]. Specialist step-down care (or accommodation with clinical support, also known as ‘medical respite’ or ‘intermediate’ care) for people who are homeless or use drugs may relieve pressure on hospitals and help staff arrange safe discharges [4042]. A pilot of specialist step-down care for hospital patients who would otherwise be discharged to street in England found that it reduced delayed transfers of care (sometimes known as “bed blocking”) and emergency readmissions [43].

Fourth, identifying ‘poly-drug’ use and reviewing medicines. Many people who use illicit opioids also use other drugs, such as cocaine, benzodiazepines, gabapentinoids, and alcohol [44,45]. Simultaneous use of multiple sedatives is particularly risky. Poly-drug use has increased over the past decade and an increasing proportion of opioid-related deaths in the UK and North America have multiple substances identified at post-mortem [46,47]. In many reports that we reviewed, patients’ poly-drug use or multiple sedative prescriptions were noted in medical records. At the time of hospital admission and acute illness, the need for pain relief may be increased and patients may use increased doses of prescription or illicit sedatives. These risks can be complex to mitigate and limiting prescriptions of these medicines could deny patients pain relief and increase use of more dangerous illicit alternatives (such as the unregulated ‘street’ benzodiazepines that are particularly common in Scotland [48]). Where clinicians know that patients use multiple sedatives, they may be able to reduce risk by discussing the patient’s needs, if necessary, with advice from pain and addiction specialists, and ensuring that patients understand how to use medicines and can be monitored by friends, relatives, or healthcare professionals.

Fifth, involving palliative care teams. Some individuals in our study had very severe illnesses and some deaths are not avoidable. However, the manner of death was often poor. Social exclusion is associated with poor access to palliative care; for example, qualitative research has shown that barriers to palliative care include stigma, insecure accommodation, and limited capacity among hostel staff [49].

Strengths and limitations

We used a unique database of coroners’ reports to explore the circumstances of deaths due to drug poisoning during and shortly after hospital admissions, which allowed us to discuss reasons for the high number of such deaths. The study has three key limitations:

First, NPSAD is an incomplete database. This is partly due to varying coverage, with some coroners not submitting reports. Coverage varies by region, which is likely to explain the small number of reports in some regions (Table 1). In addition, many reports include limited detail, meaning we could not determine whether the case met inclusion criteria. Therefore, the number of cases included in our study does not reflect the actual number of people who died in relevant circumstances. Our recent quantitative study [7] covering a similar period estimated 1,088 opioid-related deaths in the two weeks after hospital discharge, compared to 78 in this study, suggesting that we captured approximately 7% of cases. We believe that the most important selection bias is likely to occur due to coroners’ decisions to include more detailed reports for certain cases. It is possible that coroners might include more detail where the actions of health services may have contributed to a death and there may be questions relating to professional practice or neglect. Conversely, coroners may include less detail where a death is attributed to ‘natural causes’. Therefore, our sample may be more likely to include cases with themes in category A (‘hospital actions and policies), and less likely to include cases with themes in category C (‘declining health’).

Second, coroners’ reports included varying and limited data. We interpreted the available data, which was sometimes detailed and sometimes sparse. We were unable to judge the quality of clinical care based on these accounts. For example, we could not judge the appropriateness of sedative prescribing, or whether hospital staff could have prevented early discharge.

Third, the thematic framework and conclusions are dependent on the researchers’ interpretations of the data. We tried to maximise reliability between researchers by creating a coding framework together based on a sample of reports, and iteratively revising the framework together. We recognise that we have prior beliefs that affect this process, particularly our support for ‘harm reduction’ interventions that aim to increase the safety of illicit drug use rather than stop it completely. This approach might be contrasted with abstinence, zero-tolerance, or recovery-focused approaches that aim to prevent illicit drug use. Researchers with prior beliefs in these alternative paradigms might have reached different conclusions, particularly regarding tolerance of drug use in hospitals.

Conclusion

Hospital discharge is associated with increased risk of death due to illicit opioid use. Patients who use illicit opioids may leave hospital to use drugs or use drugs covertly while in hospital. Hospitals need guidance to help them care for patients who use illicit opioids, particularly in relation to improving withdrawal management, harm reduction interventions such as take-home naloxone, discharge planning including continuation of opioid agonist therapy during recovery, management of poly-sedative use, and access to palliative care.

Data Availability

The full dataset cannot be shared publicly because some coroner reports may be considered sensitive. NPSAD is managed by Dr Caroline Copeland at King’s College London. Researchers who want more information about using data from NPSAD should contact npsad@sgul.ac.uk or caroline.copeland@kcl.ac.uk.

Funding Statement

This study was conducted as part of the NIHR-funded programme ‘Improving Hospital Opiate Substitution Therapy (iHOST)’ [Ref: NIHR133022], which included funding for DL and MH. DL was also funded by a NIHR Doctoral Research Fellowship [DRF-2018-11-ST2-016]. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. TDB is supported by the Dalhousie University Internal Medicine Research Foundation Fellowship, a Canadian Institutes of Health Research Fellowship [CIHR-FRN#171259], and through the Research in Addiction Medicine Scholars (RAMS) Program (National Institutes of Health/National Institute on Drug Abuse; R25DA033211). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Zlodre J, Fazel S. All-Cause and External Mortality in Released Prisoners: Systematic Review and Meta-Analysis. Am J Public Health. 2012;102: e67–e75. doi: 10.2105/AJPH.2012.300764 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Merrall ELC, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison: Drug-related deaths after release from prison. Addiction. 2010;105: 1545–1554. doi: 10.1111/j.1360-0443.2010.02990.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357. doi: 10.1136/bmj.j1550 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Ledberg A, Reitan T. Increased risk of death immediately after discharge from compulsory care for substance abuse. Drug and Alcohol Dependence. 2022;236: 109492. doi: 10.1016/j.drugalcdep.2022.109492 [DOI] [PubMed] [Google Scholar]
  • 5.Strang J. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ. 2003;326: 959–960. doi: 10.1136/bmj.326.7396.959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Caudarella A, Dong H, Milloy MJ, Kerr T, Wood E, Hayashi K. Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. Drug and Alcohol Dependence. 2016;162: 51–55. doi: 10.1016/j.drugalcdep.2016.02.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Lewer D, Eastwood B, White M, Brothers TD, McCusker M, Copeland C, et al. Fatal opioid overdoses during and shortly after hospital admissions in England: A case-crossover study. Patel V, editor. PLoS Med. 2021;18: e1003759. doi: 10.1371/journal.pmed.1003759 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Merrall ELC, Bird SM, Hutchinson SJ. A record-linkage study of drug-related death and suicide after hospital discharge among drug-treatment clients in Scotland, 1996–2006: Drug-related death after hospital discharge. Addiction. 2013;108: 377–384. doi: 10.1111/j.1360-0443.2012.04066.x [DOI] [PubMed] [Google Scholar]
  • 9.White SR, Bird SM, Merrall ELC, Hutchinson SJ. Drugs-Related Death Soon after Hospital-Discharge among Drug Treatment Clients in Scotland: Record Linkage, Validation, and Investigation of Risk-Factors. Vrana KE, editor. PLOS ONE. 2015;10: e0141073. doi: 10.1371/journal.pone.0141073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Keen C, Kinner SA, Young JT, Snow K, Zhao B, Gan W, et al. Periods of altered risk for non-fatal drug overdose: a self-controlled case series. The Lancet Public Health. 2021;6: e249–e259. doi: 10.1016/S2468-2667(21)00007-4 [DOI] [PubMed] [Google Scholar]
  • 11.McNeil R, Small W, Wood E, Kerr T. Hospitals as a ‘risk environment’: An ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Social Science & Medicine. 2014;105: 59–66. doi: 10.1016/j.socscimed.2014.01.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fanucchi LC, Lofwall MR, Nuzzo PA, Walsh SL. In-hospital illicit drug use, substance use disorders, and acceptance of residential treatment in a prospective pilot needs assessment of hospitalized adults with severe infections from injecting drugs. Journal of Substance Abuse Treatment. 2018;92: 64–69. doi: 10.1016/j.jsat.2018.06.011 [DOI] [PubMed] [Google Scholar]
  • 13.Grewal HK, Ti L, Hayashi K, Dobrer S, Wood E, Kerr T. Illicit drug use in acute care settings. Drug and Alcohol Review. 2015;34: 499–502. doi: 10.1111/dar.12270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Brothers TD, Mosseler K, Kirkland S, Melanson P, Barrett L, Webster D. Unequal access to opioid agonist treatment and sterile injecting equipment among hospitalized patients with injection drug use-associated infective endocarditis. Gomes T, editor. PLoS ONE. 2022;17: e0263156. doi: 10.1371/journal.pone.0263156 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Strike C, Robinson S, Guta A, Tan DH, O’Leary B, Cooper C, et al. Illicit drug use while admitted to hospital: Patient and health care provider perspectives. Davidson P, editor. PLOS ONE. 2020;15: e0229713. doi: 10.1371/journal.pone.0229713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Harris M, Holland A, Lewer D, Brown M, Eastwood N, Sutton G, et al. Barriers to management of opioid withdrawal in hospitals in England: a document analysis of hospital policies on the management of substance dependence. BMC Med. 2022;20: 151. doi: 10.1186/s12916-022-02351-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Priest KC, Englander H, McCarty D. Hospital policies for opioid use disorder treatment: A policy content analysis and environmental scan checklist. General Hospital Psychiatry. 2021;70: 18–24. doi: 10.1016/j.genhosppsych.2021.02.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Harris M. Normalised pain and severe health care delay among people who inject drugs in London: Adapting cultural safety principles to promote care. Social Science & Medicine. 2020;260: 113183. doi: 10.1016/j.socscimed.2020.113183 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.van Boekel LC, Brouwers EPM, van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review. Drug and Alcohol Dependence. 2013;131: 23–35. doi: 10.1016/j.drugalcdep.2013.02.018 [DOI] [PubMed] [Google Scholar]
  • 20.Simon R, Snow R, Wakeman S. Understanding why patients with substance use disorders leave the hospital against medical advice: A qualitative study. Substance Abuse. 2019; 1–7. doi: 10.1080/08897077.2019.1671942 [DOI] [PubMed] [Google Scholar]
  • 21.Hwang SW, Li J, Gupta R, Chien V, Martin RE. What happens to patients who leave hospital against medical advice? CMAJ. 2003;168. [PMC free article] [PubMed] [Google Scholar]
  • 22.Lewer D. Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: A cohort study and nested crossover-cohort analysis. Drug and Alcohol Dependence. 2020; 7. doi: 10.1016/j.drugalcdep.2020.108343 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Valle V, Gosney H, Sinclair J. Qualitative analysis of Coroners’ data into the unnatural deaths of children and adolescents: Qualitative analysis of Coroners’ data. Child: Care, Health and Development. 2008;34: 721–731. doi: 10.1111/j.1365-2214.2008.00858.x [DOI] [PubMed] [Google Scholar]
  • 24.Kuipers P, Appleton J, Pridmore S. Thematic categorization of coroners’ reports of Indigenous and non- Indigenous suicide using the International Classification of Functioning, Disability and Health. [Google Scholar]
  • 25.Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2021 registrations. 2022. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsrelatedtodrugpoisoninginenglandandwales/2021registrations. [Google Scholar]
  • 26.Srivastava A, Thomson SB. Framework Analysis: A Qualitative Methodology for Applied Policy Research. 2009;4: 8. [Google Scholar]
  • 27.Braun V, Clarke V. Thematic Analysis: A Practical Guide. London: SAGE Publications Ltd; 2021. [Google Scholar]
  • 28.Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13: 117. doi: 10.1186/1471-2288-13-117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.The Rhodes T. ‘risk environment’: a framework for understanding and reducing drug-related harm. International Journal of Drug Policy. 2002;13: 85–94. doi: 10.1016/S0955-3959(02)00007-5 [DOI] [Google Scholar]
  • 30.Joudrey PJ, Khan MR, Wang EA, Scheidell JD, Edelman EJ, McInnes DK, et al. A conceptual model for understanding post-release opioid-related overdose risk. Addict Sci Clin Pract. 2019;14: 17. doi: 10.1186/s13722-019-0145-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Allen G, Tunnicliffe R. Drug Crime: Statistics for England and Wales. UK House of Commons Library; 2021. Report No.: 9029. Available: https://researchbriefings.files.parliament.uk/documents/CBP-9039/CBP-9039.pdf. [Google Scholar]
  • 32.Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010;341: c5475–c5475. doi: 10.1136/bmj.c5475 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Pauly B Bernie, McCall J, Browne AJ, Parker J, Mollison A. Toward Cultural Safety: Nurse and Patient Perceptions of Illicit Substance Use in a Hospitalized Setting. Advances in Nursing Science. 2015;38: 121–135. doi: 10.1097/ANS.0000000000000070 [DOI] [PubMed] [Google Scholar]
  • 34.Eswaran V, Allen KC, Bottari DC, Splawski JA, Bains S, Aks SE, et al. Take-Home Naloxone Program Implementation: Lessons Learned From Seven Chicago-Area Hospitals. Annals of Emergency Medicine. 2020;76: 318–327. doi: 10.1016/j.annemergmed.2020.02.013 [DOI] [PubMed] [Google Scholar]
  • 35.Advisory Council on the Misuse of Drugs. ACMD Naloxone Review. Advisory Council on the Misuse of Drugs; 2022. Available: https://www.gov.uk/government/publications/acmd-naloxone-review. [Google Scholar]
  • 36.Ti L, Buxton J, Harrison S, Dobrer S, Montaner J, Wood E, et al. Willingness to access an in-hospital supervised injection facility among hospitalized people who use illicit drugs: In-hospital SIF. Journal of Hospital Medicine. 2015;10: 301–306. doi: 10.1002/jhm.2344 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Nolan S, Kelian S, Kerr T, Young S, Malmgren I, Ghafari C, et al. Harm reduction in the hospital: an overdose prevention site (OPS) at a Canadian hospital. Drug and Alcohol Dependence. 2022. [cited 27 Aug 2022]. doi: 10.1016/j.drugalcdep.2022.109608 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Dong KA, Brouwer J, Johnston C, Hyshka E. Supervised consumption services for acute care hospital patients. CMAJ. 2020;192: E476–E479. doi: 10.1503/cmaj.191365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Franklin BJ, Vakili S, Huckman RS, Hosein S, Falk N, Cheng K, et al. The Inpatient Discharge Lounge as a Potential Mechanism to Mitigate Emergency Department Boarding and Crowding. Annals of Emergency Medicine. 2020;75: 704–714. doi: 10.1016/j.annemergmed.2019.12.002 [DOI] [PubMed] [Google Scholar]
  • 40.Cornes M, Whiteford M, Manthorpe J, Neale J, Byng R, Hewett N, et al. Improving hospital discharge arrangements for people who are homeless: A realist synthesis of the intermediate care literature. Health & Social Care in the Community. 2018;26: e345–e359. doi: 10.1111/hsc.12474 [DOI] [PubMed] [Google Scholar]
  • 41.Doran KM, Ragins KT, Gross CP, Zerger S. Medical Respite Programs for Homeless Patients: A Systematic Review. Journal of Health Care for the Poor and Underserved. 2013;24: 499–524. doi: 10.1353/hpu.2013.0053 [DOI] [PubMed] [Google Scholar]
  • 42.Sadowski L, Kee R, Vanderweele T, Buchanan D. Effect of a Housing and Case Management Program on Emergency Department Visits and Hospitalizations Among Chronically Ill Homeless Adults: A Randomized Trial. JAMA. 2009;301: 1771–1778. doi: 10.1001/jama.2009.561 [DOI] [PubMed] [Google Scholar]
  • 43.Cornes M, Aldridge RW, Biswell E, Byng R, Clark M, Foster G, et al. Improving care transfers for homeless patients after hospital discharge: a realist evaluation. Health Serv Deliv Res. 2021;9. doi: 10.3310/hsdr09170 [DOI] [PubMed] [Google Scholar]
  • 44.Lyndon A, Audrey S, Wells C, Burnell ES, Ingle S, Hill R, et al. Risk to heroin users of polydrug use of pregabalin or gabapentin: Risks in combining gabapentoids with heroin. Addiction. 2017;112: 1580–1589. doi: 10.1111/add.13843 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Kalk NJ, Chiu C, Sadoughi R, Baho H, Williams BD, Taylor D, et al. Fatalities associated with gabapentinoids in England (2004–2020). Brit J Clinical Pharma. 2022;88: 3911–3917. doi: 10.1111/bcp.15352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.National Records of Scotland. Drug-related Deaths in Scotland in 2021. Scottish Government; 2022. Available: https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-in-scotland/2021. [Google Scholar]
  • 47.Konefal S, Sherk A, Maloney-Hall B, Young M, Kent P, Biggar E. Polysubstance use poisoning deaths in Canada: an analysis of trends from 2014 to 2017 using mortality data. BMC Public Health. 2022;22: 269. doi: 10.1186/s12889-022-12678-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.McAuley A, Matheson C, Robertson J. From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic. International Journal of Drug Policy. 2022;100: 103512. doi: 10.1016/j.drugpo.2021.103512 [DOI] [PubMed] [Google Scholar]
  • 49.Hudson BF, Flemming K, Shulman C, Candy B. Challenges to access and provision of palliative care for people who are homeless: a systematic review of qualitative research. BMC Palliat Care. 2016;15: 96. doi: 10.1186/s12904-016-0168-6 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Charlotte Lennox

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

6 Jan 2023

PONE-D-22-27646Opioid-related deaths during hospital admissions or shortly after discharge in the United Kingdom: a thematic framework analysis of coroner reportsPLOS ONE

Dear Dr. Lewer,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We have received one review for this manuscript, however finding additional reviewers has been a challenge.  So as not to delay further, as Academic Editor, I have also undertaken a review.  The reviewer recommended that the manuscript be rejected.  However, there is significant value in this work despite the limitations and potential for bias in the source data.  The manuscript was well written and well presented.  Please address the reviewers comments (at the bottom of this email), but focusing specifically on the following:

  • Addressing the balance in the background between objective 1 & 2.  Given the issues with the data you may which to consider removing objective 1 and focus on the themes from the reports.  

  • Amend the background to make it clear what is evidenced in research and what are the authors thoughts e.g. this wording 'Potential mechanisms behind the increased risk after hospital discharge have not been studied, but could include' - Also I would recommend removing the reference to newspaper reports and just include academic research evidence.

  • Please include in the background a discussion and rationale for using thematic framework analysis to documents.

  • Please add to the limitations sections issues around bias. 

Please submit your revised manuscript by Feb 20 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Charlotte Lennox

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

If you are reporting a retrospective study of medical records or archived samples, please ensure that you have discussed whether all data were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data from their medical records used in research, please include this information

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research.

3. Thank you for stating the following in your Competing Interests section:  

No

Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now 

 This information should be included in your cover letter; we will change the online submission form on your behalf.

4. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study addresses a topic of high importance and relevance, examining the potential mechanisms underlying the increased risk of illicit drug overdose deaths following hospital discharge. Research is needed to help inform strategies for overdose prevention and engagement in harm reduction and other forms of care. However, the novel contribution of this study is unclear, given limitations in the data/approach.

The objectives of the study are to describe the characteristics of patients who died due to an opioid overdose during or shortly after discharge, and to identify the contributing factors. With respect to the second objective, the authors note that prior studies tend to rely on hospital data that offer limited contextual information with which to identify factors that contribute to fatal overdoses. However, several potential contributing factors are outlined in the Background/literature review, including some backed with citations of prior research. It isn’t clear whether these factors were identified empirically in these prior studies or through speculation, clinical experience, or other means. Further, no attention is given in the Background to establishing a rationale for the first objective. Without this information, the rationale and novel contribution of the current study (which identifies many of these same factors) are not clearly established.

The data source has limitations that may restrict the impact of this work beyond what is acknowledged in the Discussion. The limited coverage of fatal overdoses, in combination with the voluntary nature of reporting, differences in levels of detail, and unknown (but likely) reporting biases within and across geographical areas and/or coroners, all detract from data quality. Given questions of representativeness, it is not clear that these data are suited to answer the first objective (providing a description of patient characteristics). Some variables in Table 1 have a high level of missing values, hindering interpretation. Further, unknown biases affected what is and isn’t recorded across coroners may have impacted the identification of contributing factors. In describing study limitations, the authors note the relatively low coverage of fatal overdoses in the data source but that they do not think there’s reason to suspect bias. This seems insufficient justification.

Additional more minor comments are as follows. Use of the risk environments concept fits for this study, but more detail would be appreciated on how this framework was used in the analysis (e.g., what dimensions of context were considered and whether these were limited to hospital contexts). It seems like attention to community contexts may have also been informative, such as what services are available, what is known about the illicit drug supply, its composition and potential variation across communities. Although it makes sense that focus would be placed on hospital contexts, community contexts will also have affected overdoses as well as what gets potential recorded in coroners’ reports – was this considered?

In table 2, the link between the example case and theme isn’t always clear; alternative explanations seem possible without more information/context. For example, under 7) poor health leading to reduced access to treatment – is the lack of evidence of recent methadone use (even in the context of poor/worsening health) sufficient to suggest access to treatment was impacted by poor health? This seems speculative, and there are other potential explanations for why OAT was not evident. Perhaps the case description is not fully indicative of the information contained in the report, meaning there were other reasons to attribute this death to a lack of access to treatment. It just isn’t clear in what is provided, and so raises questions about how attributions were made during analysis.

In the context of the toxic and volatile illicit drug supply, the loss of opportunities for engaging people in potentially life-saving harm reduction and health care during hospital and other service encounters is a major issue that needs to be remedied. The quotes in this paper are terribly sad and serve to highlight important shortcomings in a way that affects the reader. However, these shortcomings appear to have been demonstrated to some degree previously; when combined with the methodological limitations of this study, its overall contribution to the literature appears limited.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 1

Charlotte Lennox

13 Mar 2023

Opioid-related deaths during hospital admissions or shortly after discharge in the United Kingdom: a thematic framework analysis of coroner reports

PONE-D-22-27646R1

Dear Dr. Lewer,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Charlotte Lennox

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Charlotte Lennox

11 Apr 2023

PONE-D-22-27646R1

Opioid-related deaths during hospital admissions or shortly after discharge in the United Kingdom: a thematic framework analysis of coroner reports

Dear Dr. Lewer:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Charlotte Lennox

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: response_to_reviews_v1.pdf

    Data Availability Statement

    The full dataset cannot be shared publicly because some coroner reports may be considered sensitive. NPSAD is managed by Dr Caroline Copeland at King’s College London. Researchers who want more information about using data from NPSAD should contact npsad@sgul.ac.uk or caroline.copeland@kcl.ac.uk.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES